Taliglucerase alfa

DRUG5 trials

Sponsors

Pfizer

Conditions

Gaucher Disease

Phase 3

Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

CompletedNCT00705939

PfizerGaucher Disease

Start: 2008-06-30End: 2013-08-31Updated: 2018-10-04

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

CompletedNCT00712348

PfizerGaucher Disease

Start: 2008-12-31End: 2013-05-31Updated: 2018-10-04

A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

CompletedNCT01411228

PfizerGaucher Disease

Start: 2011-09-30End: 2014-08-31Updated: 2018-09-07

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

CompletedNCT01422187

PfizerGaucher Disease

Start: 2011-08-31End: 2014-09-30Updated: 2023-04-19

Phase 4

A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

CompletedNCT01132690

PfizerGaucher Disease

Start: 2010-08-31End: 2012-07-31Updated: 2018-10-05

Related Papers

Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase

Blood Cells Molecules and Diseases2016-10-2037 citations

Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease

Blood Cells Molecules and Diseases2016-07-1827 citations

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

American Journal of Hematology2016-04-2226 citations

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease

American Journal of Hematology2016-03-1923 citations

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease

PLoS ONE2015-06-0811 citations

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

Blood Cells Molecules and Diseases2014-11-0733 citations

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.

2014-06-1839 citations